1. Scrip
  2. >>Business
  3. >>Earnings

Madrigal’s Rezdiffra Continues Its Solid Launch

 
• By Joseph Haas

With $180m in sales during its first nine months on the US market, the first approved MASH drug still tops projections. Madrigal predicts continued growth in 2025, with EU entry expected.

Set of Three Increasing Size Red and White Cartoon Spaceships on Dark Background
Madrigal's Rezdiffra continued its early growth through three quarters on the market • Source: Alamy

Madrigal’s successful launch of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom) continued during the fourth quarter and on 26 February the company predicted strong year-over-year sales growth for 2025, driven partially by expected EU approval and initial launch in Germany later this year.

Key Takeaways
  • Madrigal continues to beat Wall Street projections for the launch of Rezdiffra, the first approved MASH drug.
  • Rezdiffra brought in $180m in 2024, including $103m in Q4, a 66% sequential increase from Q3

The Conshohocken, PA-based company also reported two-year data from a cohort of MASH patients with cirrhosis from an ongoing study,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Therapy Areas

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.